Expansion Opportunity Aegros recently completed a Haemafrac plasma fractionation facility and is expanding capabilities in Macquarie Park, Sydney, signaling readiness for scaled production and potential pharmaceutical supply partnerships. Sales focus: equipment, process engineering, and contract manufacturing services for PDMP production.

Strategic Leadership With Damian Thornton acting CEO and Ray Nolan appointed Chairman, the company is undergoing leadership-driven growth and governance strengthening, creating openings for high-trust, long-term collaboration, advisory services, and large-scale project financing conversations.

Funding Signals A $20M funding infusion from a major investor highlights investor confidence and available capital for expansion initiatives. Potential sales angles include advanced manufacturing technology, automation integrations, scale-up consulting, and strategic partnerships.

Digital & Tech Stack Aegros utilizes a modern tech stack (Power Platform, SAP, Azure, SOLIDWORKS, e-commerce tools) indicating openness to digital transformation, data analytics, ERP optimization, and automation solutions that can streamline GMP-compliant production planning and supply chain.

Market & Compliance Operating in regenerative plasma therapies with a mission to improve access suggests alignment with healthcare payers, regulatory consulting, quality management systems, and high-purity PDMP supply; opportunities exist in validation services, regulatory tech, and patient-focused distribution.